Source comparison
Melanotan-2 for Men Over 40: Clinical Comparison
| Parameter | Melanotan-2 (Research-Grade) | Testosterone Replacement Therapy | PDE5 Inhibitors (Sildenafil) | Professional Assessment ||—|—|—|—|| Mechanism of Action | MC1R/MC3R/MC4R receptor agonist. Increases alpha-MSH signalling | Androgen receptor activat
This comparison does not assign a generated winner or score.
- | Parameter | Melanotan-2 (Research-Grade) | Testosterone Replacement Therapy | PDE5 Inhibitors (Sildenafil) | Professional Assessment ||—|—|—|—|| Mechanism of Action | MC1R/MC3R/MC4R receptor agonist. Increases alpha-MSH signalling | Androgen receptor activation. Replaces endogenous testosterone | Phosphodiesterase-5 inhibition. Increases cGMP in smooth muscle | Melanotan-2 addresses central arousal pathways; TRT and PDE5 inhibitors work through different mechanisms and can be used concurrently || Onset of Sexual Function Effect | 30–60 minutes subcutaneous injection | 2–4 weeks (transdermal), 1–2 weeks (injectable esters) | 30–60 minutes oral administration | Melanotan-2 and PDE5 inhibitors produce acute effects; TRT requires sustained administration || Effect on Spontaneous Erections | Increases frequency and duration via MC4R-mediated dopamine release | Restores nocturnal erections and morning erections when testosterone is deficient | No effect on spontaneous erections. Works only